The CORE diabetes model

Current Medical Research and Opinion

Volumn 20, Issue SUPPL. 1, 2004, Pages S1-S3

  Brändle, Michael ^a   Herman, William H ^b,c,d,e  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMORBIDITY; COMPUTER MODEL; COMPUTER SIMULATION; DISEASE COURSE; EDITORIAL; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR;

EID: 5344249310     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X1962     Document Type: Editorial

References (21)

1. Taylor TN, Chrischilles EA. Economic evaluation of interventions in endocrinology. Endocrinol Metab Clin North Am 26:67-87, 1997.
2. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996.
3. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 6:9-17, 2003.
4. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20:725-34, 1997.
5. Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract;50 Suppl 3:S15-46, 2000.
6. Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock H, Wenzel H. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract;50 Suppl 3:S47-S56, 2000.
7. Stevens R, Adler A, Gray A, Briggs A, Holman R. Life-expectancy projection by modeling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50 (Suppl. 3):S5-S13, 2000.
8. Stevens R, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 101:671-9, 2001.
9. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HAW, Holman RR. Risk of stroke in type 2 diabetes estimated by the UKPDS risk engine (UKPDS 60). Stroke 33:1776-81, 2002.
10. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care, 26:3093-101, 2003.
11. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 276:1409-15, 1996.
12. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, Manninen D, Garfield SA, Copley-Merriman C, Maier W, Eastman JF, Kotsanos J, Cowie CC, Harris M. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:735-44, 1997.
13. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of Type II diabetes. Diabetologia;44:2140-55, 2001.
14. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-51, 2002.
15. Palmer AJ, Roze S, Foos V, Lurati FM, Valentine WJ, Minshall ME. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin:20(Suppl 1), 2004.
16. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lammert M, Spinas GA. Validation of the CORE Diabetes Model. Curr Med Res Opin:20(Suppl 1), 2004.
17. Palmer AJ, Roze S, Lammert M, Nicklasson L, Gall M, Spinas GA. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 patients with inadequate glycemic control. An application of the CORE Diabetes Model in type 2 diabetes. Curr Med Res Opin: 20(Suppl. 1), 2004.
18. 1c, lipids, and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin: 20(Suppl. 1), 2004.
19. Palmer AJ, Roze S, Valentine WJ, Lammert M, Oglesby A, Hayes C, Spinas GA. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model. Curr Med Res Opin: 20(Suppl. 1), 2004.
20. Palmer AJ, Roze S, Valentine WJ, Lammert M, Nicklasson L, Spinas GA. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Curr Med Res Opin: 20(Suppl. 1), 2004.
21. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353:617-22; 1999.